A single institutional retrospective study evaluating incidence, characteristics, and risk factors of venous thromboembolism in adolescent and young adult acute lymphoblastic leukemia patients receiving peg-asparaginase
Latest Information Update: 07 Jun 2019
At a glance
- Drugs Pegaspargase (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
Most Recent Events
- 07 Jun 2019 New trial record
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology